Koros Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 12 Year, 15 Days
- Last Filing with ROC 31 Mar 2022
About Koros Pharma
Koros Pharma Private Limited (KPPL) is a Private Limited Indian Non-Government Company incorporated in India on 04 February 2013 and has a history of 12 years. Its registered office is in Delhi, India.
The Company is engaged in the Trading Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Shipra Jain, Sarvendra Mishra, Rajan Srivastava, and One other member serve as directors at the Company.
Company Details
- Location
Delhi, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U51909DL2013PTC247858
- Company No.
247858
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 Feb 2013
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
What products or services does Koros Pharma Private Limited offer?
Koros Pharma Private Limited offers a wide range of products and services, including Common Disease Medicines, Antiseptic Mouthwashes, Nutraceuticals & Dietary Supplements, Mineral Supplement, Digestive System Drugs & Medicines, Pre & Probiotic Capsule, Vitamin Tablets & Capsules.
Who are the key members and board of directors at Koros Pharma?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ravindra Upadhyay  | Director | 03-Mar-2018 | Current |
| Shipra Jain | Director | 04-Feb-2013 | Current |
| Sarvendra Mishra | Director | 05-Jun-2017 | Current |
| Rajan Srivastava | Director | 03-Mar-2018 | Current |
Financial Performance of Koros Pharma.
Koros Pharma Private Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Koros Pharma?
In 2017, Koros Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Koros Orthocare LlpShipra Jain is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Koros Pharma?
Unlock and access historical data on people associated with Koros Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Koros Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Koros Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
